ApoB and Lp(a): The Cholesterol Tests Your Annual Physical Skips

Why ApoB

Why ApoB Beats LDL-C as a Risk Marker

LDL-cholesterol measures the cholesterol content of LDL particles. ApoB counts the particles themselves — one ApoB molecule per LDL, VLDL, IDL, and Lp(a). Atherosclerosis is driven by particle count entering the arterial wall, not by the cholesterol carried inside.

When LDL-C and ApoB disagree (common in insulin resistance, metabolic syndrome, and high-triglyceride states), ApoB is the more accurate measure of cardiovascular risk. Multiple meta-analyses and Mendelian randomization studies support ApoB as the dominant lipid risk marker.

European and Canadian cardiology guidelines have moved toward ApoB-guided treatment. U.S. guidelines still center LDL-C but increasingly endorse ApoB for risk refinement, particularly in metabolic-syndrome and discordant patients.

Why Lp(a)

Why Every Adult Should Know Their Lp(a)

Lp(a) is an LDL particle bound to a unique apolipoprotein(a) tail. Levels are 80–90% genetically determined, set for life, and change very little with diet, exercise, or statins.

Roughly 20% of adults have elevated Lp(a) (>50 mg/dL or >125 nmol/L). Elevated Lp(a) independently raises risk of heart attack, stroke, and aortic stenosis — often presenting as 'unexplained' early cardiovascular disease.

Because Lp(a) is genetic and stable, current guidance is to measure it once in adulthood. If elevated, management focuses on aggressive control of every other modifiable risk factor (ApoB, blood pressure, smoking, diabetes) while emerging Lp(a)-lowering drugs (pelacarsen, olpasiran, lepodisiran) work through phase III trials.

Why most physicals miss them

Why Most Annual Physicals Don't Include These

A standard primary-care lipid panel reports total cholesterol, LDL-C (often calculated, not measured), HDL-C, and triglycerides. ApoB and Lp(a) are not included by default, are not always covered by insurance for screening, and many physicians weren't trained to use them.

That gap is closing — preventive cardiology, longevity, and concierge programs now order both routinely — but if you have not specifically asked, you almost certainly haven't been tested.

Targets

Targets and What the Numbers Mean

ApoB targets (preventive-cardiology framing):

• ·Optimal: <60 mg/dL
• ·Average: 80–100 mg/dL
• ·Elevated: >120 mg/dL

Lp(a) thresholds:

• ·Desirable: <30 mg/dL (or <75 nmol/L)
• ·Borderline: 30–50 mg/dL
• ·High: >50 mg/dL (>125 nmol/L) — meaningfully elevated CV risk
• ·Very high: >100 mg/dL — premature CAD risk substantially elevated

Cost

What ApoB and Lp(a) Cost in 2026

ApoB: $20–$80 cash. Often covered by insurance with a cardiovascular risk diagnosis or established hyperlipidemia. Direct-to-consumer labs (Quest, Labcorp, Marek, Ulta Lab Tests) typically $30–$60.

Lp(a): $30–$80 cash. Increasingly covered by insurance given updated guideline endorsement of one-time screening.

Many longevity and concierge programs include both in baseline panels at no incremental cost.

Pricing reviewed June 2026.

What to do

If Your Numbers Are High

Elevated ApoB: treated like high LDL — diet, exercise, weight, then statin and/or ezetimibe and/or PCSK9 inhibitor as risk dictates. Target ApoB <60 mg/dL in patients at high cardiovascular risk.

Elevated Lp(a): no FDA-approved Lp(a)-specific drug yet. Manage every other modifiable risk factor aggressively; consider adding low-dose aspirin in select cases per physician judgment; PCSK9 inhibitors lower Lp(a) modestly.

Family screening: first-degree relatives of patients with elevated Lp(a) should also be tested, given the genetic transmission.